News Releases

Read all the latest news from Bristol Myers Squibb Belgium here.

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis >
Bristol Myers Squibb today announced that the European Commission has approved Sotyktu (deucravacitinib), a first-in-class, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy, representing a new way of treating this chronic immune-mediated disease.

Kick-off Women’s History Month & 2023 theme: celebrating women’s stories >
On March 8th, we celebrated International Women’s Day. The focus this year is on gender equity and celebrating women telling their stories. The B-NOW Belgian Chapter was thrilled to invite BMS Braine-l’Alleud-based employees to its first Lunch & Learn session of the year. 

Innovative research pushes boundaries in the fight against cancer >
Cancer treatments are getting better, more diverse and more numerous. Although we still die from cancer, we are also increasingly recovering from it... Research, pharmaceutical companies, governments and private individuals are joining forces to fight cancer together.

Sabine de Beuf
Contact details for media

Didn't find the information you were looking for or do you have further questions? Please contact us directly. We will be happy to help you out!

 

Sabine De Beuf

Head of Corporate Communications, Public Affairs & Patient Advocacy

 

Phone number: +32 2 352 76 11

 

E-mail: pressinfo.belgium@bms.com

For all other questions

If you are not a member of the press and have a non-media related question then find the right contact information here. This will enable us to help you faster!